Global Axial Spondyloarthritis Management Market to Reach USD 7.3 Billion by 2033 at a 5.1% of CAGR Amid Rising Prevalence and Demand for Effective Treatments

Axial Spondyloarthritis Management Market

The global axial spondyloarthritis (axSpA) management market, valued at USD 4.22 billion in 2022, is anticipated to expand steadily, projected to reach approximately USD 7.3 billion by 2033. This growth, expected at a CAGR of 5.1% from 2023 to 2033, is driven by a rising prevalence of axSpA and the increasing demand for efficient treatment options. From 2018 to 2022, the market demonstrated a CAGR of 3.5%, reflecting a growing focus on improving patient outcomes in axial spondyloarthritis care.

Axial spondyloarthritis, a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints, leads to significant pain and stiffness in the back and hips. The axSpA management market encompasses a range of drugs, therapies, and medical devices specifically designed to alleviate symptoms and improve mobility for those with the condition.

As awareness of axSpA rises and treatment options advance, healthcare providers and pharmaceutical companies are investing in innovative solutions to address this complex condition. The market is poised to benefit from ongoing research and development, offering new opportunities to enhance the quality of life for patients worldwide.

Market Competition

Key players in the axial Spondyloarthritis management market are AbbVie, Pfizer, Amgen, Janssen Biotech, Pozen, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly and Company, Kyowa Kirin, Celgene, Inmagene Biopharmaceuticals

• AbbVie has developed Rinvoq, a medication that was approved by the FDA in August 2021 for the treatment of active axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS). It is an oral, small molecule Janus kinase (JAK) inhibitor that works by blocking certain enzymes involved in the inflammatory process.
• Janssen Biotech has also made significant contributions to the axial Spondyloarthritis (axSpA) management market, primarily through its drug Simponi (golimumab). Simponi is a biologic medication that was approved by the FDA in 2011 for the treatment of axSpA, including ankylosing spondylitis (AS). It works by inhibiting tumor necrosis factor (TNF), a pro-inflammatory cytokine that is involved in the development of axSpA.

Key Companies Profiled

• AbbVie
• Pfizer
• Amgen
• Janssen Biotech
• Pozen
• Iroko Pharmaceuticals
• Syntex Pharmaceuticals
• Horizon Pharma
• Eli Lilly and Company
• Kyowa Kirin
• Celgene
• Inmagene Biopharmaceuticals

A Full Report Overview

Key Segments Profiled in the Axial Spondyloarthritis Management Industry Survey

Type:

• Ankylosing Spondylitis Treatment
• Non-Radiographic Axial Spondyloarthritis Treatment

Drug Class:

• Non-steroidal anti-inflammatory drugs
• Glucocorticoids
• Anti-rheumatic drugs

End User:

• Hospital
• Clinics
• Rehabilitation Centre
• Academic Research Institutes

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube